NBRV - Nabriva Therapeutics under pressure on $25.4M registered direct offering

Nabriva Therapeutics (NBRV) trades 17.2% down premarket after entering into a definitive agreement with certain healthcare-focused and institutional investors for the purchase and sale of 10.4M shares and warrants to purchase up to 5.18M shares in a registered direct offering.Each ordinary share and accompanying warrant are being sold together at $2.4525, and each pre-funded warrant and accompanying warrant for combined purchase price of $2.4425.Warrants have an exercise price of $2.39/share, are exercisable on the issuance date and will expire on the five-year anniversary of the issuance date.Gross proceeds are estimated at ~$25.4M.Offering expected to close on or about Mar.3.

For further details see:

Nabriva Therapeutics under pressure on $25.4M registered direct offering